Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

November 19, 2019

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

US-based Dicerna Pharmaceuticals and Novo Nordisk have signed a deal worth up to around $607m to discover and develop drugs for liver-related cardio-metabolic diseases.

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases